56.24
Phibro Animal Health Corp stock is traded at $56.24, with a volume of 185.37K.
It is up +2.85% in the last 24 hours and up +1.30% over the past month.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
See More
Previous Close:
$54.68
Open:
$55.15
24h Volume:
185.37K
Relative Volume:
0.63
Market Cap:
$2.28B
Revenue:
$1.46B
Net Income/Loss:
$92.09M
P/E Ratio:
24.93
EPS:
2.2555
Net Cash Flow:
$47.29M
1W Performance:
+3.59%
1M Performance:
+1.30%
6M Performance:
+36.67%
1Y Performance:
+187.97%
Phibro Animal Health Corp Stock (PAHC) Company Profile
Name
Phibro Animal Health Corp
Sector
Phone
201-329-7300
Address
GLENPOINTE CENTRE EAST, 3RD FLOOR, TEANECK, NJ
Compare PAHC vs TAK, ZTS, TEVA, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
PAHC
Phibro Animal Health Corp
|
56.24 | 2.22B | 1.46B | 92.09M | 47.29M | 2.2555 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Phibro Animal Health Corp Stock (PAHC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-15-26 | Initiated | Citigroup | Neutral |
| Jul-07-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-16-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-10-24 | Initiated | JP Morgan | Neutral |
| Dec-07-23 | Initiated | Exane BNP Paribas | Underperform |
| Dec-21-22 | Initiated | ROTH Capital | Buy |
| Jul-25-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-10-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Nov-18-21 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Jul-07-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Aug-06-20 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Feb-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Jan-28-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-29-19 | Reiterated | BofA/Merrill | Underperform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| May-23-19 | Initiated | Guggenheim | Neutral |
| May-09-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Aug-23-17 | Resumed | BofA/Merrill | Underperform |
| Jun-02-17 | Downgrade | Credit Suisse | Outperform → Neutral |
| Dec-15-16 | Initiated | Piper Jaffray | Overweight |
| Nov-11-16 | Downgrade | Macquarie | Neutral → Underperform |
| Nov-10-16 | Downgrade | Gabelli & Co | Buy → Hold |
| Apr-11-16 | Reiterated | Guggenheim | Buy |
| Feb-04-16 | Initiated | Credit Suisse | Outperform |
| Jan-15-16 | Downgrade | Barclays | Overweight → Underweight |
| Sep-30-15 | Initiated | Gabelli & Co | Buy |
| Apr-24-15 | Reiterated | Barclays | Overweight |
| Apr-21-15 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-06-14 | Initiated | Barclays | Overweight |
View All
Phibro Animal Health Corp Stock (PAHC) Latest News
Phibro Animal Health Corporation Launches Companywide Sustainable - The National Law Review
[8-K] PHIBRO ANIMAL HEALTH CORP Reports Material Event - Stock Titan
Phibro sets June 24 payout for $0.12-a-share quarterly dividend - Stock Titan
Phibro launches low-carbon feed ingredients to target Scope 3 emissions - Stock Titan
How Investors Are Reacting To Phibro Animal Health (PAHC) Expanding Its Revolving Credit Facility - Yahoo Finance
MSN Money - MSN
Phibro Animal Health Corp (PAHC) Stock Up 3.1% but GF Value Says Overvalued -- GF Score: 73/100 - GuruFocus
Phibro Animal Health (NASDAQ:PAHC) CEO Sells $393,606.40 in Stock - MarketBeat
Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells 7,040 Shares of Stock - MarketBeat
Phibro Animal Health CEO Bendheim-linked entity sells $1.1m stock - Investing.com
CEO-associated BFI Co. trims Phibro (PAHC) stake under 10b5-1 plan - Stock Titan
Phibro Animal Health (NASDAQ: PAHC) raises revolver to $435M - Stock Titan
Phibro Animal Health Corp (NASDAQ: PAHC) — Vanguard holds 5.06% stake - Stock Titan
Precision Wealth Strategies LLC Purchases Shares of 41,973 Phibro Animal Health Corporation $PAHC - MarketBeat
Phibro investors get Q3 results May 6, webcast the next morning - Stock Titan
Phibro Animal Health Corporation to Host Webcast and Conference Call on Third Quarter Results - ChartMill
Phibro Animal Health Corporation Announces Regulatory Framework Change in Brazil for Antimicrobials - The National Law Review
Phibro Animal Health (PAHC) to Release Earnings on Wednesday - MarketBeat
PAHC Stock Price, Quote & Chart | PHIBRO ANIMAL HEALTH CORP-A (NASDAQ:PAHC) - ChartMill
Phibro Animal Health Corp (PAHC) Shares Fall 3.3% -- GF Value Sa - GuruFocus
Phibro Animal Health's (PAHC) CEO Sold 21,120 Shares for $1.2 Million - Yahoo Finance
Zacks Industry Outlook Highlights Phibro Animal Health, BioLife Solutions, Omeros and Brainsway - Yahoo Finance
Phibro Animal Health (PAHC) to Adapt to New Brazilian Antimicrob - GuruFocus
Assessing Phibro Animal Health (PAHC) Valuation After Powerful Share Price Momentum - Yahoo Finance
Brazil Bans Key Feed Antibiotics, Forcing Industry to Adapt - BriefGlance
Phibro Animal Health announces Brazil ban on growth‑promotion antimicrobials; 180‑day transition limits FY2026 impact - TradingView
Axecap Investments LLC Lowers Stake in Phibro Animal Health Corporation $PAHC - MarketBeat
Controlling holder of Phibro Animal Health (PAHC) reports 48.3% stake - Stock Titan
Phibro Animal Health CEO Bendheim sells $1.16m in PAHC stock - Investing.com Canada
Jack Bendheim Sells 7,040 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock - MarketBeat
BFI Co., LLC linked to PAHC (PAHC) sells 21,120 Class A shares - Stock Titan
Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know - Yahoo Finance
Is It Too Late To Consider Phibro Animal Health (PAHC) After A 234.5% Rally? - Yahoo Finance
Phibro Animal Health (NASDAQ:PAHC) Upgraded at Citigroup - MarketBeat
Phibro Animal Health (PAHC) director sells $1.2m in shares By Investing.com - Investing.com India
Phibro Animal Health (PAHC) director sells $1.2m in shares - Investing.com
Pre-planned stock sales by Phibro (PAHC) CEO-linked entity - Stock Titan
Lobbying Update: $150,000 of PHIBRO ANIMAL HEALTH CORPORATION lobbying was just disclosed - Quiver Quantitative
PAHC Initiates Coverage by Citigroup -- Price Target Announced a - GuruFocus
Phibro Animal Health Corp. Opens with 5.07% Gain, Outperforming S&P 500 - Markets Mojo
Phibro Animal Health Corp. Hits New 52-Week High of $59.67 - Markets Mojo
Phibro Animal Health : PAHC - 24/7 Wall St.
Phibro Animal Health (NASDAQ:PAHC) Trading Down 4.5%Should You Sell? - MarketBeat
Is This the Right Time to Add PAHC Stock to Your Portfolio? - Yahoo Finance
Phibro director Joyce J. Lee to resign effective April 15, 2026 - TradingView
Board member Joyce Lee to leave Phibro Animal Health (NASDAQ: PAHC) - Stock Titan
Phibro Animal Health Corp Stock (PAHC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):